Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jordan R. Krieger"'
Autor:
Ali S Antar, Tudor Borza, Ethan Richmond, Glenn O Allen, Jordan R Krieger, Margaret A Knoedler, Christopher M Manakas, Wei Huang, Dan R Gralnek, Matthew D Grimes
Publikováno v:
Journal of Urology. 209
Autor:
J. Louis Hinshaw, Fred T. Lee, Sean P. Hedican, Jordan R. Krieger, Paul E. Laeseke, Timothy J. Ziemlewicz, Tudor Borza, E. Jason Abel, Sara L. Best, Lindsay Stratchko, Marci L. Alexander, Timothy McCormick, Stephen Y. Nakada, Shane A. Wells
Publikováno v:
Journal of endourology. 35(S2)
Management options for small renal masses include active surveillance, partial nephrectomy, radical nephrectomy, and thermal ablation. For tumors typically ≤3 cm in size, thermal ablation is a good option for those desiring an alternative to surger
Autor:
Barry R. Zirkin, Natasza Posielski, Arthur L. Burnett, Brian Le, Haolin Chen, Jordan R. Krieger
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Osteocalcin (OC) has been shown to regulate testosterone (T) production in mice and may offer a promising target for treatment of hypogonadal men. Yet, the relationship ...
Publikováno v:
Sexual medicine reviews. 7(3)
Introduction Peyronie’s disease is an acquired condition of the connective tissue of the penis that affects 0.5–20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, p
Publikováno v:
Sexual medicine reviews. 6(4)
Background Vasculogenic erectile dysfunction (ED) is one of the leading causes of male sexual dysfunction. In the past decade, multiple studies have examined the use of low-intensity extracorporeal shockwave therapy (Li-ESWT) for the treatment of ED.
Autor:
John T. Sigalos, Jordan R. Krieger, Mark S. Hockenberry, Edgar W. Kirby, Larry I. Lipshultz, Alexander W. Pastuszak
Publikováno v:
Journal of Urology. 197
Autor:
Luke Fletcher, Zahida Yasin, Gustavo A. Rivero, Martha P. Mims, Chizoba Ifeorah, Alka Mulchandani, Jordan R. Krieger, Andre Catic, Sarvari Venkata Yellapragada
Publikováno v:
Journal of Clinical Oncology. 35:e19515-e19515
e19515 Background: Proteasome inhibitors (PIs) are efficacious in multiple myeloma (MM). In randomized phase 3 studies Carfilzomib doubled the progression free survival (PFS) compared to Bortezomib from 9.4 mo to 18.7 mo (ENDEAVOR study) in relapsed